Actively Recruiting
TAD After Chemotherapy in Locally Advanced Breast Cancer
Led by Hospital Universitari de Bellvitge · Updated on 2025-09-10
162
Participants Needed
2
Research Sites
278 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is an observational study to validate target axillary dissection (TAD) in locally advanced tumors (cN2 and/or cT4).
CONDITIONS
Official Title
TAD After Chemotherapy in Locally Advanced Breast Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Axillary lymph node metastasis proven by cytology
- Clinical or radiological N2a with at least 4 suspicious lymph nodes on axillary ultrasound at diagnosis
- Extensive T4 tumor requiring axillary lymphadenectomy according to current clinical criteria
- Planned or ongoing neoadjuvant chemotherapy
You will not qualify if you...
- cN3 confirmed by imaging tests
- N2 due to internal mammary lymph node involvement (N2b)
- Tumors with luminal A molecular subtype
- Patients receiving neoadjuvant endocrine therapy
- Patients with local recurrences or metastatic tumors
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Hospital de Bellvitge
L'Hospitalet de Llobregat, Barcelona, Spain, 08907
Actively Recruiting
2
Hospital Clínico y Provincial de Barcelona
Barcelona, Spain, 08036
Actively Recruiting
Research Team
A
Amparo García-Tejedor, MDPhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here